文献速递贫血与红细胞疾病血栓与止血白血病

血液系统恶性肿瘤的胚系遗传易感性

Germline Genetic Predisposition to Hematologic Malignancy.
PubMed 文献 · J Clin Oncol · 2017-02-13

血液系统恶性肿瘤由体细胞或胚系突变驱动。二代测序促进了个体化诊断与治疗策略的发展。本文综述了胚系易感性患者的诊断与管理通用方法,并讨论了基因组检测在临床实践中的应用与局限性。

要点

  • 胚系易感性诊断影响治疗选择、并发症风险、供者选择及监测策略。
  • 无典型临床特征或家族史的患者也可能存在遗传性血液肿瘤综合征。
  • 基因组检测选择增多,临床医生需应对新的诊断挑战。

核心结论

  • 认识胚系易感性有助于优化治疗选择、供者选择、并发症评估和监测策略以改善临床结局。

研究设计与样本

  • 综述,讨论胚系易感性患者的诊断与管理通用方法及基因组检测的应用与局限性。

主要发现

  • 血液系统恶性肿瘤的驱动突变可为体细胞或胚系突变。
  • 二代DNA测序技术促进了个体化诊断评估和定制治疗策略的发展。
  • 无经典临床特征或可疑家族史的患者也可能存在遗传性血液肿瘤综合征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 基因组检测是快速发展的领域,临床医生面临越来越多的检测选择。
  • 基因组检测在临床实践中的应用与局限性有待进一步考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Development of hematologic malignancies is driven by mutations that may be somatic or germline. Availability of next-generation DNA sequencing technologies has facilitated the development of individualized diagnostic evaluations and tailored treatment strategies. Until now, such personalized medical approaches have largely centered on prognostic stratification and treatment strategies informed by acquired somatic mutations. The role of germline mutations in children and adults with hematologic malignancies was previously underappreciated. Diagnosis of an inherited predisposition to hematologic malignancy informs choice of therapy, risk of treatment-related complications, donor selection for hematopoietic stem cell transplantation, evaluation of comorbidities, and surveillance strategies to improve clinical outcomes. The recognition that patients with inherited hematologic malignancy syndromes may present without classic clinical stigmata or suspicious family history has led to increased reliance on genetic testing, which, in turn, has raised new diagnostic challenges. Genomic testing is a rapidly evolving field with an increasing number of choices for testing for the practicing clinician to navigate. This review will discuss general approaches to diagnosis and management of patients with germline predisposition to hematology malignancies and will consider applications and limitations of genomic testing in clinical practice.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Furutani E, Shimamura A. Germline Genetic Predisposition to Hematologic Malignancy. J Clin Oncol. 2017. PMID: 28297620. doi:10.1200/JCO.2016.70.8644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。